ConcertAI debuts Precision Suit, a GenAI powered platform built on CARAai to speed up decisions in clinical trials and market execution.
ConcertAI has launched Precision Suit, a GenAI and agentic AI-powered product line designed to help life sciences teams work faster and smarter. Built on CARAai, the platform uses multi-modal, AI-curated data to process complex oncology datasets in real time. It converts EMR, genomic, claims, and social data into actionable insights. This reduces delays across clinical research, trial design, and market strategy.
The suite includes three tools: Precision Explorer, Precision Trials, and Precision GTM. Precision Explorer helps medical and HEOR teams generate evidence-backed insights in half the time. It simplifies cohort creation and hypothesis testing using curated oncology data and GenAI interfaces. Teams can deliver high-quality, guideline-aligned insights in minutes—not weeks—cutting millions in research costs.
Precision Trials uses agentic AI to optimize site selection, improve recruitment, and reduce trial amendments. It enables real-time adjustments that shorten Phase II and III timelines and save up to $4 million per trial. For commercialization, Precision GTM™ unifies data from multiple sources to track physician behavior, treatment trends, and care standards. This speeds up launch decisions and generates up to $7 million in value per oncology brand.
At the core of this system is Precision360, which delivers insights from unstructured datasets with less than a one-week data lag. This allows for near-instant strategic actions. By combining agentic AI with tailored oncology applications, ConcertAI enables faster decisions, better patient outcomes, and significant cost savings across the life sciences industry.